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Bioresponsive antisense DNA 
gold nanobeacons as a hybrid 
in vivo theranostics platform for 
the inhibition of cancer cells and 
metastasis
Chenchen Bao1,*, João Conde2,3,*, James Curtin4, Natalie Artzi2,5, Furong Tian6 & 
Daxiang Cui1
Gold nanobeacons can be used as a powerful tool for cancer theranostics. Here, we proposed a 
nanomaterial platform based on gold nanobeacons to detect, target and inhibit the expression of a 
mutant Kras gene in an in vivo murine gastric cancer model. The conjugation of fluorescently-labeled 
antisense DNA hairpin oligonucleotides to the surface of gold nanoparticles enables using their 
localized surface plasmon resonance properties to directly track the delivery to the primary gastric 
tumor and to lung metastatic sites. The fluorescently labeled nanobeacons reports on the interaction 
with the target as the fluorescent Cy3 signal is quenched by the gold nanoparticle and only emit light 
following conjugation to the Kras target owing to reorganization and opening of the nanobeacons, 
thus increasing the distance between the dye and the quencher. The systemic administration of the 
anti-Kras nanobeacons resulted in approximately 60% tumor size reduction and a 90% reduction in 
tumor vascularization. More important, the inhibition of the Kras gene expression in gastric tumors 
prevents the occurrence of metastasis to lung (80% reduction), increasing mice survival in more than 
85%. Our developed platform can be easily adjusted to hybridize with any specific target and provide 
facile diagnosis and treatment for neoplastic diseases.
Amolecular beacon is a hairpin DNA single-stranded oligonucleotide, which transports a dye and a 
quencher at both ends. In the absence of a complementary target, the stem-loop structure is closed 
imposing the dye and the quencher to a close proximity, causing a fluorescence quenching. In the pres-
ence of a complementary target, the stem-loop sequence is opened and the molecular beacon hybridizes, 
1Institute of Nano Biomedicine and Engineering, Key Lab. of Thin Film and Microfabrication Technology of Ministry 
of Education, Department of instrument science and engineering, School of Electronic Information and Electrical 
Engineering, National Center for Translational Medicine, Shanghai Jiao Tong University, P.R.China. 2Massachusetts 
Institute of Technology, Institute for Medical Engineering and Science, Harvard-MIT Division for Health Sciences 
and Technology, Cambridge, Massachusetts, USA. 3School of Engineering and Materials Science, Queen Mary 
University of London, London, UK. 4School of Food Science and Environmental Health, College of Sciences and 
Health, Dublin Institute of Technology, Cathal Brugha Street, Dublin, Ireland. 5Department of Anesthesiology, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. 6Focas Research Institute, 
Dublin Institute of Technology, Camden Row, Dublin, Ireland. *These authors contributed equally to this work. 
Correspondence and requests for materials should be addressed to J.C. (email: jdconde@mit.edu) or F.T. (email: 
furong.tian@dit.ie)
Received: 01 April 2015
Accepted: 23 June 2015
Published: 20 July 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:12297 | DOi: 10.1038/srep12297
creating a double-stranded 3D structure. With the opening of the stem-loop, the spatial distance between 
dye and quencher increases and the fluorescence is reestablished1.
Molecular beacons can be optimized to match with specific experimental requirements. By controlling 
the length of both stem and loop a broad range of temperatures for target detection can be achieved, 
as well as lower signal-to-background ratios and/or different dissociation rate constants2. Although very 
productive for in vitro experiments, utilization of molecular beacons ex vivo and in vivo has not been 
successful, probably due to the reduced chemical stability of nucleic acids in biological media and fragile 
protection against serum nucleases.
The growing field of nanotechnology has brought a wide variety of tools for molecular analysis 
and clinical imaging and theranostics with increased sensitivity and specificity3–9. Due to their opti-
cal properties, nanomaterials and nanoparticles in particular have been used for nucleic acid screen-
ing methodologies, specifically through thiolated DNA oligonucleotides capable of recognizing specific 
nucleotide sequences10–13. The combination of the optical properties of nanoparticles with the demon-
strated advantages of standard molecular beacons can prove to be extremely useful in molecular biology. 
Gold nanoparticles (AuNPs) have been demonstrated to modulate dye emission in their vicinity14, from 
fluorescence quenching to fluorescence enhancement15, which suggests AuNPs as an excellent substitute 
of classic quenchers. Additionally, AuNPs provide the possibility for in vivo studies of DNA hairpin-like 
structures as they offer protection against degradation by nucleases16,17 and can act as both transfection 
and targeting vectors18–20 controlling crucial cellular processes such as antisense DNA and RNA inter-
ference pathways.
Antisense DNA21,22 pathways have emerged as powerful and useful tools to block gene function and 
for sequence-specific posttranscriptional gene silencing. The discovery of their prominent role in regu-
lation of specific gene expression in numerous disease states, such as cancer resulted into an enormous 
effort towards the development of new efficient delivery systems that control those pathways23,24.
Gastric cancer (GC) is a prevalent cancer in Asia, with most new cases and deaths in China, Japan 
and Korea. It is the third most common malignant tumor and causes 300,000 deaths in China each 
year25. The 5-year survival rate for patients with advanced GC is only around 10%; the rest of the patients 
usually have median survival times of 8–12 months26. Improving the survival of GC patients requires the 
development of novel diagnostic and anti-tumor therapy. A Kras mutation have recently been described 
in gastrointestinal stromal tumors (GISTs), yielded a high number of KIT mutant GISTs and reported 
also in wild type for KIT and PDGFRA27,28.
Kras is one of the most commonly activated oncogenes in human cancer, with 17 to 25% of all human 
tumors harboring an activating Kras mutation29 In addition to gastrointestinal tumors, over 90% of pan-
creatic adenocarcinomas, 30%–50% of colorectal cancers, 55% of thyroid cancers, 35% of lung cancers, 
and 35% of rhabdomyosarcomas harbor mutated RAS genes30.
Previously, Conde et al. developed an in vitro gold-nanobeacon system as a proof-of-concept to follow 
RNA synthesis in real time in bulky solutions and for antisense DNA and RNA interference (RNAi), 
from gene specific silencing to silence-the-silencers in vitro only31–33. From these studies, the authors 
proved the potential of a single molecular nanoconjugate to intersect all RNA pathways in vitro: from 
gene specific downregulation (ie. inhibit a GFP reporter) to silencing siRNA and miRNA pathways31.
Here, we used antisense DNA gold nanobeacons to selective inhibition of mutant Kras in vivo. These 
bioresponsive gold nanobeacons have a unique and positive effect on metastatic cell colonization in 
the lungs in a syngeneic and spontaneous gastric cancer mice model. This nanobeacons platform is 
of high therapeutic potential and serves as a theranostics system of orthotopic gastric tumors but also 
as anti-metastasis treatment, where nanobeacons show a strong involvement in both local and distant 
lesions.
Therefore, we designed and developed an in vivo universal tool based on AuNPs functionalized with 
a dye labeled hairpin-DNA, i.e. gold-nanobeacon to inhibit simultaneously cancer cells and metastasis 
in a murine tumor model following systemic administration via the antisense silencing of a mutant 
transcript of Kras gene (see Fig. 1A). The NPs used in this study consist of a AuNP core decorated with 
and a thiol-DNA-hairpin labelled with a Cy3 dye. A polyethylene glycol (PEG) is also used as a spacer 
between the antisense DNA hairpins, increasing the nanostructure stability in biological medium32,33 
(see Supplementary Figure S1 for PEG optimization and quantification). Under hairpin configuration, 
the proximity of the Cy3 dye to the AuNP (that works as quencher) leads to fluorescence quenching. 
Hybridization of the DNA hairpin to a complementary target (i.e. Kras mRNA) restores fluorescence 
emission due to the gold nanobeacons’ conformational reorganization that causes the fluorophore and 
the quencher to part from each other, yielding a quantitative response. These molecular beacons have 
the ability to interlock or hybridize with the target Kras mRNA (blocking specific translation initiation 
signals of Kras gene) thus inhibiting the translation of the target protein.
In addition to designing anti-Kras nanobeacon that detects and inhibits Kras mRNA, a nonsense nano-
beacon (that does not hybridize with any target) was developed as an internal control (Supplementary 
Figure S2 and Table S1). Oligomers sequences and 2-dimensional structures of the beacons at 37 °C are 
depicted in Supplementary Table S1.
Transmission electron microscopy (TEM) images of the DNA antisense gold nanobeacons anti-Kras 
showed an average diameter of the gold core of 15.1 ± 1.1 nm (Supplementary Figure S3A). The final bea-
con:NP ratio was around 45:1 (see Supplementary Table S2). The mean particle diameter of nanobeacons 
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anti-Kras is 25.9 (±3.5) nm and nanobeacon nonsense is 24.7 (±2.9) nm as measured by DLS and with 
an SPR peak at 525 nm as evaluated by UV-Vis extinction profiles (Supplementary Figure S3B), and 
slightly anionic (−25.6±1.2 mV) via zeta-potential (Supplementary Table S2).
Figure 1. (A) Gold nanoparticles (AuNPs) functionalized with a dye (Cy3) labeled hairpin-DNA, i.e. gold-
nanobeacon (Au-nanobeacon), designed to detect, target and inhibit the expression of Kras gene in an in 
vivo murine gastric cancer model. Under hairpin configuration, proximity to gold nanoparticles leads to 
fluorescence quenching; hybridization to a complementary target restores fluorescence emission due to 
the Au-nanobeacons’ conformational reorganization that causes the dye and the AuNP to part from each 
other. The scheme was designed and produced on Adobe Illustrator CC 2014 by J.Conde. (B) Cy3 emission 
at 570 nm after hybridization with increasing amounts of complementary and non-complementary ssRNA 
targets (0 to 3E-05 M). (C) Flow cytometry analysis comparing nanobeacon anti-Kras treated cells to 
nanobeacon nonsense. (D) The silencing effect was expressed as a concentration-dependent decrease in 
Kras relative expression. Anti-Kras nanobeacons showed potent silencing effects in human gastric cancer 
cells (MGC-803) with an ED50 between 1 and 5 nM. (E) Live imaging images of anti-Kras nanobeacon 
(previously incubated with Kras complementary target) compared to nanonsense nanobeacon and a blank 
tube.
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The stability of gold nanobeacons towards increasing concentrations of Glutathione (GSH) and DNase 
was also evaluated (Supplementary Figure S4A,B). These data confirms the stability of the gold nano-
beacons to intracellular concentrations of GSH (Supplementary Figure S4A) and DNase (Supplementary 
Figure S4B).
The fluorescent emission from the Cy3 (Emi = 570 nm) is efficiently quenched by the ~14 nm AuNP due 
to a nanosurface energy transfer (NSET) effect34. The fluorescence is “OFF” when the hairpin-DNA-Cy3 
is closed (i.e. no hybridization with the complementary target). The fluorescence is “ON” when the 
hairpin-DNA-Cy3 hybridizes with a Kras complementary target and an increase in Cy3 emission occurs 
(Supplementary Figure S5). It is worth noting that the fluorescence emission intensity of Cy3-labeled 
DNA oligo is significantly decreased after the reaction with gold nanoparticles, due to the quenching 
effect between the Cy3 dye and the gold surface. This effect occurs once a good overlap between dye 
emission and quencher (AuNP) absorbance is observed, providing an indication of the quenching effi-
ciency (Supplementary Figure S6A). When the concentration of Cy3-labeled DNA oligo was fixed at 
1 μ M, the increase in AuNPs concentration from 0 to 8 nM in the reaction mixture resulted in a signifi-
cant increase in Cy3 fluorescence quenching (Supplementary Figure S6B), demonstrating the presence of 
NSET between the Cy3 groups and the AuNPs. These data showed a quenching efficiency of nearly 90% 
when the concentration of AuNPs reached 3 nM, whereas nearly 100% when the concentration of AuNPs 
reached 8 nM. Conversely, the Cy3 emission can be restored after hybridization with the complementary 
ssDNA Kras target. Increasing amounts of complementary target results in elevated emission form the 
Cy3 dye at 570 nm until reaching a plateau at 1E–05M of target (Fig. 1B).
Indeed, analytical flow cytometry data confirmed the signal specificity of the nanobeacon incubated 
in human gastric cancer cells (MGC-803), where a substantial increase in Cy3 intensity signal is observed 
only for nanobeacons anti-Kras when compared to nanobeacon nonsense (Fig. 1C).
We next assessed in vitro gene silencing efficiency in the human gastric cancer cell line MGC-803 
of both anti-Kras and nonsense nanobeacons. The ability of both anti-Kras and nonsense nanobeacons 
to silence Kras was evaluated in gastric cancer cells, where only the anti-Kras nanobeacons provided 
a robust knockdown in a dose dependent manner, with a median effective dose (ED50) between 1 and 
5 nM. Specifically, more than 80% silencing could be observed at the mRNA level by qPCR at a dose of 
50 nM at 48 hours of incubation (Fig. 1D).
In order to corroborate flow cytometry data (Fig.  1C) the fluorescence signal from gold nanobea-
cons previously incubated with a ssRNA Kras target (mimicking Kras mRNA) was evaluated by the live 
imaging system (Fig.  1E). As expected, only anti-Kras nanobeacons produce a significant increase in 
fluorescence signal, when compared to nonsense nanobeacons and a blank.
The efficiency of the anti-Kras nanobeacon probes in sensing and in silencing gastric cancer cells in 
vivo was evaluated in an orthotopic gastric cancer mice model. Human gastric cancer cell line MGC-803 
was used to generate the orthotopic tumor model in nude mice. After the formation of the tumor tissue, 
the tumor tissue stability in nude mice was passaged three more generations in subcutaneous tumors, 
before transferred into nude stomach via small animal surgery. An OB adhesive construction of ortho-
topic gastric tumor transplantation was applied for tumor tissue adhesion. OB glue paste technique is 
commonly used to establish nude mouse human gastric cancer orthotopic transplantation models. The 
OB glue paste technique is easy to perform and the biological behaviors of the nude mice human gas-
tric cancer orthotopic transplantation models established with this technique are similar to the natural 
processes of growth and metastasis of human gastric cancer35. Four weeks after the OB surgery and the 
establishment of the orthotopic model, mice were tail-vein injected with gold nanobeacons and in vivo 
imaging was used to track simultaneously organs biodistribution, tumor size and nanobeacon probes 
signal after hybridization to the target monitored by fluorescence emission over a period of 120 hours 
(5 days) following nanobeacons injection (Fig. 2). The trial endpoint was 5 days once after that the signal 
from the nanobeacons decreased dramatically. In vivo imaging of mice administered with 5 or 50 nM 
of anti-Kras nanobeacons or nonsense nanobeacons (50 nM) revealed that only nanobeacons anti-Kras 
were able to promote efficient and sustained detection of primary gastric tumor (Fig.  2A,B), with an 
approximately 60% tumor size reduction 5 days after intravenous injection, when compared to nonsense 
nanobeacon. Concerning nanobeacon probes imaging, fluorescence images of treated mice revealed, as 
expected, that fluorescence signal is OFF at day 0 (0.5 hours after tail-vein injection) and is turned ON 
4 hours later, and maintains the signal until 120 hours (Fig. 2A), only for the anti-Kras nanobeacons and 
not for the nonsense nanobeacons.
Recently, a similar system using gold nanobeacons for both gene and drug delivery in a multid-
rug resistance mice model was described36. The authors reported that gold nanobeacons could enter 
cells probably via an endocythosis-mediated mechanism. Confocal images of breast cancer cells further 
revealed that the gold nanobeacons were colocalized in intracellular organelles such as endosomes and/
or lysosomes at 24 hours and could escape out of this organelles at 48 hours. If the majority of gold nano-
beacons escape lysosome the mechanism behind the cellular uptake and endosomal escape is probably 
an endocytosis mechanism mediated by caveolae receptors, once the escape from the endosomal com-
partments happens before lysosomal activation. This mechanism represents an alternative pathway with 
distinct cellular compartments to avoid lysosomal degradation. The anionic nature of the nanobeacons 
may be endocytosed through the interaction with the positive site of the proteins in membrane, and they 
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can be highly captured by cells because of their repulsive interactions with the negatively charged cell 
surface; and are more likely to use caveolae-dependent endocytosis.
Representative images of whole body organs and resected tumors in mice treated with 5 and 50 nM 
of anti-Kras nanobeacons is depicted in Fig. 2B. Other organs showed residual accumulation, consistent 
with previous work reported for AuNPs28. These results showed that anti-Kras nanobeacons accumulate 
also in lungs. As evaluated by the quantification of nanobeacons signal the anti-Kras nanobeacons at 5 
and 50 nM accumulate preferentially at the gastric tumor site and lungs (Fig. 2C). Quantification analy-
sis of tumor ROI also revealed the specificity of the anti-Kras nanobeacons to the gastric tumors, when 
compared to nonsense nanobeacons (Supplementary Figure S7). Moreover, monitoring tumor ROI as 
Figure 2. (A) Epi-fluorescence analysis of nude mice bearing orthotopic human gastric cancer cells, 0.5, 4, 
24, 72 and 120 hours after tail-vein injection of nonsense (50 nM) and anti-Kras (5 and 50 nM) nanobeacons. 
Arrows represent gastric tumors. (B) Epi-fluorescence images of whole body organs to evaluate selective 
signal from the gold nanobeacons accumulated in tumors. (C) Quantification of anti-Kras nanobeacons 
signal in the region of interest (ROI) in major organs (liver, kidney, spleen, heart, lung and tumor) at 5 days 
after nanobeacons injection.
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a function of time after treatment revealed a significant tumor size reduction using 50 nM of anti-Kras 
nanobeacons, when compared with 5 nM.
It is well known that metastasis occur frequently from gastric tumors to the lungs37. Therefore, in 
order to track gold nanobeacons in tumor and lung tissues plasmonic-tunable Raman/FITR imaging 
spectroscopy was used (Fig. 3). Figure 3A shows the FTIR image of gold nanoparticles only. The cancer 
tissue was under processed with standard cryosection steps using regular histopathology methodologies. 
The sections were spread on 2 mm CaF2 substrate and remained embedded in paraffin, without any 
chemical treatment such as dewaxing. The reason for this is to prevent any further chemical modification 
Figure 3. ATR-FTIR imaging of the tumor tissue for mice treated with naked nanoparticles (A), NB@
nonsense (B) and NB@Anti-Kras (D) on tumor region. (C) The spectra extracted from the tumor region 
with nonsense nanobeacons weaker bands at 1712, 1662, 1493 cm−1 and new bands at 1750 and 1100 cm−1. 
(E) The spectra extracted from the tumor region of mice treated with anti-Kras nanobeacons show stronger 
bands at 1712, 1662, 1493 and 1082 cm−1.
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of the sample due to reagents and also to create some degree of refractive index matching, thus reducing 
the spectral distortion due to Mie scattering38.
At the spectral region with frequencies 750–4000 cm−1, absorption was more intense for the anti-Kras 
nanobeacons treated mice. The spectrum extracted from the tumor region shows absorption peaks at 
1712, 1662, 1493 and 1082 cm−1, representing the DNA phosphate backbone stretching vibrations of 
anti-Kras nanobeacons (Fig.  3E), while the spectrum extracted from the tumor region with nonsense 
nanobeacons shows weaker bands at 1712, 1662, 1493 and 1082 cm−1. The infrared band at 1712 cm−1 
exemplifies the H-bonded C2 = O2 stretching vibration of thymines (T) from the third strand in T*A–T 
triplex, where the third strand is involved in a reverse Hoogsteen base pair scheme. The band at 1662 cm−1 
is attributed primarily to thymine stretching vibrations of C4 = O4 bonds. The band at 1493 cm−1 appears 
due to the ring stretching vibrations of cytosine (C = C) respectively39–42. In FTIR spectra of nonsense 
nanobeacons treated mice a new peak at 1750 cm−1 appears and the peak at 1082 cm−1 (that corresponds 
to the vibration intensity of the phosphoric acid groups (PO2−) with a symmetric stretching at, which has 
been extensively reported for several other material types43) is shifted to 1100 cm−1. Therefore, for the 
PO2− symmetric stretching frequency, the band from the anti-Kras nanobeacons treated mice exhibit a 
peak at 1082 cm−1 in the original profile (Fig. 3E), and the peak from the nonsense nanobeacons treated 
mice appeared at 1100 cm−1 (Fig. 3C). Higher spectra peaks can be observed in anti-Kras nanobeacons 
when compared to nonsense nanobeacon, probably due to higher values of free energy in secondary 
structure formation (Supplementary Figure S2).
Spatial variations in the absorbance of these bands indicate the ability of micro ATR-FTIR imaging to 
probe chemical differences in tumor area (Fig. 3B,D). In addition to biological tissue, macro ATR-FTIR 
imaging has also been applied to study biomaterial processes including the plasmonic-tunable Raman/
FITR imaging spectroscopy, which results show that anti-Kras nanobeacons accumulate extensively in 
the tumor tissue when compared to the nonsense nanobeacons.
Nevertheless, both nanobeacons accumulate similarly in lung tissue (Fig. 4A,B). In order to validate 
these data, inductively coupled plasma mass spectrometry (ICP-MS) showed that after 5 days of treat-
ment, only anti-Kras nanobeacons accumulate extensively in tumor tissue; whereas both anti-Kras and 
nonsense nanobeacons accumulate in lung tissue (with a 5-fold increase when compared to other organs, 
such as heart, liver, spleen, kidney – Fig.  4C). Other organs showed residual accumulation, consistent 
with previous work reported for AuNPs44.
The higher gold content in the tumor tissue by the anti-Kras nanobeacons may be due to a delay 
in nanoparticles recycling by the cells, once the anti-Kras nanobeacons may stay bound to the target 
mRNA. Once the nonsense nanobeacons do not present any function within the cell they excreted by 
the cell much faster than the anti-Kras nanobeacons. This fact is corroborated by the data on the nano-
beacons’ in vitro uptake kinetics measured by ICP-MS (see Supplementary Figure S8).
To validate safety assessment, 5 days after injection with nanobeacons organs were harvested from 
mice and H&E stained for routine pathological analysis (Supplementary Figure S9). H&E staining showed 
that, in vivo administration of both nonsense and anti-Kras nanobeacons did not cause any significant 
damage in several organs (i.e. heart, liver, spleen, and kidney).
However, histological analysis in tumor tissue showed evidence of extensive reduced vascularization 
for anti-Kras nanobeacons loaded when compared to nonsense nanobeacons (Fig. 5A and Supplementary 
Figure S9), in accordance with tumor size reduction (see Fig. 2B). Moreover, H&E staining of lung tissue 
show that nonsense nanobeacon exposed groups exhibited inflammatory accumulation at the broncho-
alveolar junction and thickened local alveolar walls (Fig. 5A and Supplementary Figure S9). Significant 
reduction in severe interstitial infiltration of inflammatory cells is noted in the anti-Kras nanobeacon 
treated group. Nonsense nanobeacon treated group showed a predominance of mononuclear cells, as well 
as perivascular and peribronchiolar edema, occurrence of hypercellularity and thickened local alveolar 
walls and septa and increased number of tumoral clones (arrows in Fig. 5A). These histological images 
confirmed an evident decrease (~90%) in the incidence and severity of tumor clones and metastasis in 
lung from mice treated with anti-Kras nanobeacons, after 5 days of exposure.
Previous studies have been shown that metastatic cells could be established in the lungs before their 
oncogenic transformation, forming intravascular colonies in the lungs with concomitant invasion of 
the organ45,46. In fact, the incidence of pulmonary metastatic lung cancer from gastric cancer has been 
reported as approximately 50%, based on autopsy results36,47.
In order to confirm the reduction in number of gastric cancer metastasis into lung tissue, immuno-
colocalization staining’s were performed. Representative confocal microscopy images of lung tissue, con-
firmed the persistence of gastric tumor cells presence in the lungs (Fig. 5B) only in the group treated with 
nonsense nanobeacons. Alexa-Fluor® 594-labeled anti-human vimentin and FITC-labeled anti-human 
HLA antibodies specific for human antigens (that do not cross-react with either mouse fibroblasts or 
tumor cells) were used to visualize human gastric cancer metastasis in lung from mice treated with 
nanobeacons, as described elsewhere48. Vimentin is a type III intermediate filament (IF) protein that 
is expressed in mesenchymal cells, and is often used as a marker of mesenchymal-derived cells or cells 
undergoing an epithelial-to-mesenchymal transition (EMT) during both normal development and met-
astatic progression49. On the other hand, the human leucocyte antigen (HLA) system is the major his-
tocompatibility complex in humans, playing an essential role in the immune recognition of tumor cells 
that escape the immune system, and lead to lung metastasis for example50.
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Vimentin and HLA expression is much higher in lung tissue treated with nonsense nanobeacons, 
when compared to anti-Kras nanobeacons (Fig. 5B). These results corroborate the decrease in the num-
ber of gastric cancer metastasis in lung tissue (~80% decrease) via the administration of anti-Kras nano-
beacons (Fig. 5C).
Next, we hypothesized that anti-Kras nanobeacons would enhance the likelihood of observing an 
increase in mice survival, as their administration results in significant tumor size reduction and in the 
decrease of number of metastatic lung cells. Accordingly, nude mice bearing human gastric xenograft 
tumors were treated with both nonsense and anti-Kras nanobeacons (50 nM). Animals treated with 
anti-Kras nanobeacons survived significantly longer (***P < 0.005 – Fig.  5D) compared to nonsense 
nanobeacon group. The results indicated that the observed survival extension of more than 85% could 
be attributed to both the inhibition of gastric tumor cells in the primary tumor and by the extensive 
reduction in the occurrence of metastasis in lung. The improved outcome in tumor-bearing mice receiv-
ing anti-Kras nanobeacon treatment strongly supports the extraordinary potential of these nanoparticles 
as adjuvant agents to anticancer therapies. Effectively targeting metastases has proven to be extremely 
challenging due to the difficulty in overcoming biological barriers surrounding the cancer cells and the 
lack of tissue specificity. These bioresponsive antisense DNA gold nanobeacons prove to be a successful 
platform to target both cancer cells and metastasis. Our developed platform can be easily adjusted to 
hybridize with any specific target and provide rapid and cheap diagnosis and treatment for neoplastic 
diseases.
Taken together, treatment with antisense DNA anti-Kras nanobeacons efficiently and selectively 
reduced the primary gastric tumor size by 60% and impaired the establishment of lung metastatic cells in 
more than 80% of the cases, thus increasing mice survival in more than 85%. Our data indicate that gas-
tric tumor-associated cells shed from the primary tumor together with accompanying cancer cells survive 
to a secondary site and proliferate within the metastatic nodules in the lung in the absence of anti-Kras 
nanobeacons treatment. Following selective Kras inhibition via antisense DNA nanoprobes, these unique 
Figure 4. (A) ATR-FTIR image of nonsense and anti-Kras nanobeacons showing the integrated absorbance 
at 1712 cm−1 on tumor and lung area. (B) Relative ATR-FTIR intensity at 1712 cm−1 for nonsense and anti-
Kras nanobeacons accumulated in tumor and lung tissues. (C) Quantification of gold accumulated in tissues 
by inductively coupled plasma mass spectrometry (ICP-MS). Biodistribution data of nonsense and anti-Kras 
nanobeacons in major organs (liver, spleen, lung, kidney, heart and tumor) at 5 days after nanobeacons 
injection. Note the difference in tumor accumulation between the nonsense and anti-Kras nanobeacons 
and in comparison with the other major organs. Both nonsense and anti-Kras nanobeacons accumulate 
significantly in lungs. The SD (error bars) were calculated based on six animals (n = 6) per each study group.
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nanobeacons have a positive effect on metastatic cell colonization in the lungs in a syngeneic and spon-
taneous mice model. In summary, the nanobeacons platform is of high therapeutic potential and serves 
as a theranostics and neoadjuvant therapy of orthotopic gastric tumors but also as anti-metastasis treat-
ment, where nanobeacons show a strong involvement in both local and distant lesions. This platform 
can be further designed to selectively and specifically silence any target gene to overcome a broad range 
of cancerous diseases.
Methods
Synthesis of citrate gold nanoparticles. Gold nanoparticles, with an average diameter of 
13.2 ± 2.1 nm, were synthesized by the citrate reduction method described by Lee and Meisel51. Briefly, 
225 mL of 1 mM hydrogen tetrachloroaureate (III) hydrate (Sigma) (88.61 mg) was solved in 500 ml of 
distilled water, heated, and stirred under reflux. When the solution boils, 25 mL of 38.8 mM sodium 
citrate dihydrate (Sigma) (285 mg) was added resulting in a red solution. The solution is kept under 
ebullition with vigorous stirring and protected from light for 30 minutes. After this, the solution is cooled 
Figure 5. (A) Histological analysis of gastric tumor and lung tissue indicating a reduced vascularization in 
the primary tumor and a decrease in tumoral clones in lung tissue treated with anti-Kras nanobeacons only. 
Nonsense nanobeacons group present inflammatory cells accumulation at bronchoalveolar junction and 
thickened local alveolar walls and high prevalence of tumoral clones (arrows). (B) Representative confocal 
microscopy images of lung tissue immunostaining, confirming the persistence of gastric cancer metastasis in 
the lungs. Blue: DAPI nuclear stain; red: Alexa-Fluor® 594-labeled anti-human vimentin; green: FITC-labeled 
anti-human HLA. Scale bars, 20 μ m. (C) anti-Kras nanobeacons treatment significantly reduced the number 
of spontaneous lung metastasis in gastric cancer model (***P < 0.005, n = 6 mice). (D) Kaplan-Meier 
survival curves for mice treated with nonsense (black) and anti-Kras (red) nanobeacons using Log-Rank 
test. Data points represent group mean ± SD (n = 6, ***P < 0.005).
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down and kept protected from light. Citrate gold nanoparticles were characterized by Transmission 
Electron Microscopy (TEM) and UV-Vis molecular absorption spectra.
Synthesis of PEGylated-Gold nanoparticles. Functionalization of PEGylated gold nanoparticles 
was carried out using commercial hetero-functional poly(ethylene glycol) (PEG) functionalized with a 
30% saturated surface of α -Mercapto-ω -carboxy PEG solution (HS-C2H4-CONH-PEG-O-C3H6-COOH, 
MW. 3500 Da, Sigma) as described elsewhere52,53. The 30% of saturated PEG layer allows the incorpo-
ration of additional thiolated components, such as the thiolated DNA-hairpin-Cy3. Briefly, 10 nM of 
the citrate-gold nanoparticles were mixed with 0.006 mg/mL of PEG solution in an aqueous solution of 
SDS (0.028%). After this, the mixture was incubated for 16 hours at room temperature. Excess PEG was 
removed by centrifugation (15,000 × rpm, 30 min, 4 °C), and quantified by a modification of the Ellman’s 
Assay (see Supplementary Information S2 for complete protocol and quantification methods).
Synthesis of Gold Nanobeacons. Two different sequences of Gold Nanobeacons were prepared: 
a nanobeacon anti-Kras (detects and inhibits Kras mRNA) and a nanobeacon nonsense (designed to 
not hybridizes with any target within the genome) (Supplementary Table S1 for thiol-DNA-hairpin Cy3 
sequences). Briefly, the thiolated oligonucleotides (Sigma) – thiol-DNA-hairpin Cy3 were suspended in 
1 mL of 0.1 M dithiothreitol (DTT, Sigma), extracted three times with ethyl acetate and further puri-
fied through a desalting NAP-5 column (GE Healthcare) using 10 mM phosphate buffer (pH 8) as elu-
ent. Following oligonucleotide quantification via UV/Vis spectroscopy, each oligomer was added to the 
AuNP-PEG solution in a 50:1 ratio. AGE I solution (2% (w/v) SDS, 10 mM phosphate buffer (pH 8)) was 
added to the mixture to achieve a final concentration of 10 mM phosphate buffer (pH 8), 0.01% (w/v) 
SDS. The solution was sonicated for 10 seconds using an ultrasound bath and incubated at room temper-
ature for 20 minutes. Afterwards, the ionic strength of the solution was increased sequentially in 50 mM 
NaCl increments by adding the required volume of AGE II solution (1.5 M NaCl, 0.01% (w/v) SDS, 
10 mM phosphate buffer (pH 8)) up to a final concentration of 10 mM phosphate buffer (pH 8), 0.3 M 
NaCl, 0.01% (w/v) SDS. After each increment, the solution was sonicated for 10 seconds and incubated 
at room temperature for 20 minutes before the next increment. Following the last addition, the solution 
was left to rest for additional 16 hours at room temperature. Then, the functionalized gold nanobeacons 
were centrifuged for 20 minutes at 15,000 × rpm, the oily precipitate washed three times with MilliQ 
water, and redispersed in MilliQ water. The resulting gold nanobeacons were stored in the dark at 4 °C 
until further use. Characterization of the gold nanobeacons was performed by Dynamic Light Scattering 
– DLS (Wyatt Dyna Pro Plate Reader), UV/Vis Spectroscopy and TEM (see Supplementary Table S2).
Specificity assays for Gold Nanobeacons. For the detection of specific targets, 2.5 nM of nanobea-
con anti-Kras and nanobeacon nonsense in 10 mM of phosphate buffer pH 7 was added to 5 nM of com-
plementary Kras target (Sigma). All measurements were performed in a microplate reader (Varioskan 
Flash Multimode Reader, Thermo Scientific) programmed to incubate the reactions for 120 min at 37 °C 
while recording the fluorescence intensity every 2 minutes at an excitation wavelength of 550 nm for 
Cy3-labeled gold nanobeacon.
In vitro Gold Nanobeacon’s delivery. Human gastric cancer MGC-803 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 4 mM glutamine, 10% heat 
inactivated fetal bovine serum (Invitrogen), 100 U/ml penicillin and 100 μ g/ml streptomycin (Invitrogen) 
and maintained at 37 °C in 5% CO2. Cells were seeded at a density of 1 × 105 cells/well in 24-well plates 
and grown for 24 hours prior to incubation of nanobeacons. On the day of incubation, the cells were 
approximately 50% confluent. For flow cytometry, data were acquired on FACS LSR Fortessa HTS-1 (BD 
Biosciences) flow cytometer.
Quantitative PCR. Total RNA from Human gastric cancer cell line MGC-803 was extracted using 
RNeasy Plus Mini Kit (Qiagen) according to the manufacture’s protocol. cDNA was produced using 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using 500 ng of total RNA. 
qRT-PCR was performed with Taqman probes FAM-MGB for Kras and GAPDH (Applied Biosystems). 
GAPDH was used as a reference gene. The reactions were processed using Light Cycler 480 II Real-time 
PCR machine (Roche) using TaqMan® Gene Expression Master Mix (Applied Biosystems) under the 
following cycling steps: 2 min at 50 °C for UNG activation; 10 min at 95 °C; 40 cycles at 95 °C for 15 s; 
60 °C for 60 s. At least three independent repeats for each experiment were carried out. Gene expression 
was determined as a difference in fold after normalizing to the housekeeping gene GAPDH.
Construction of orthotopic gastric cancer mice model. All animal experiments were approved 
by the Institutional Animal Care and Use Committee of Shanghai Jiao Tong University (NO.SYXK2007-
0025). The animal experimentation methods were carried out in accordance with the approved and 
relevant guidelines and regulations. Nude mice (nu/nu, female, 18 g, 4 weeks old) were purchased from 
the Shanghai SLAC Laboratory animal Co. Ltd and housed in SPF grade animal center. Subcutaneous 
gastric cancer (GC) tissues at the exponential growth phase loaded by nude mice were resected asepti-
cally. Necrotic tissues were cut away, and the remaining tumor tissues were scissor-minced into pieces 
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around 1–2 mm in diameter in 4 °C Hanks’ balanced salt solution, and each piece was adjusted to be 
30 mg with scissors. Before the surgery, all mice were fasting for at least 8 hours. Mice were anesthetized 
with 5% trichloraldehyde hydrate, with 4 μ L/g weight and an incision was made through the left upper 
abdominal pararectal line and peritoneum. The stomach wall was carefully exposed, and a part of the 
serosal membrane, about 2 mm in diameter, in the middle of the greater curvature of the glandular 
stomach was mechanically scratched with ophthalmic knives. A tumor piece of 30 mg was then fixed on 
the injured site of the serosal surface with OB glue (Guang Zhou Baiyun Ltd, China). The stomach was 
then returned to the peritoneal cavity, and the abdominal wall and skin were closed with 9-0 ophthalmic 
sutures. The animals were kept on warm electric blanket at 37 °C until analepsia and kept separately in 
an SPF environment.
FTIR Instrumentation. ATR spectra were recorded with the Perkin Elmer Spotlight 400 N Universal 
Attenuated Total Reflectance (UATR) accessory of the spectrometer, which employs a 9-bounce dia-
mond top-plate for this analysis. Sample penetration is both wavenumber and sample dependent, but is 
typically of at the order of 1 mm. In ATR mode, spectral data were the result of 4 scans, with a spectral 
resolution of 8 cm−1. Tissue samples were seed on CaF2 crystal and air dry for 10 min prior to recording. 
A background spectrum was also recorded and automatically subtracted by the software.
Analysis of tumor growth and mice survival. Non-invasive longitudinal monitoring of tumor 
progression was followed by scanning mice with the Bruker In-Vivo F PRO imaging system from mice 
bearing gastric tumors (n = 6 animals per treated group). Whole-animal imaging was performed at the 
indicated time points – 0.5, 4, 24, 72 and 120 hours after nanobeacons injection. Kaplan-Meier survival 
curves were designed by evaluating mice survival follow up. In order to compare the survival distribu-
tions of mice treated with anti-Kras and nonsense nanobeacons log-rank tests were performed.
Histology and immunolocalisation. After mice have been sacrificed and perfused with sterile PBS, 
organs were snap-frozen in optimum cutting temperature compound (Tissue-Tek® ) and cut on a cryostat 
microtome and air-dried overnight. Frozen sections were thawed and stained for hematoxylin and eosin 
using standard procedures. Stained tissue sections were then imaged by light microscopy. For immu-
nolocalisation, the tumor and lung tissues were embedded and sliced into a 3 μ m section. After fixation 
with 4% paraformaldehyde in PBS, lung tissue sections were treated with blocking solution containing 
4% rabbit serum in PBS. For metastasis detection, the lung tissue slide was incubated with Alexa Fluor® 
594-labeled anti-human vimentin antibody (1:250 Abcam) and FITC-labeled anti-human HLA antibody 
(1:100, BioLegend) in PBS containing 1% BSA for 60 min, and was washed three times in PBS. Nuclei 
were DAPI stained before slide mounting with Fluoromount™ Aqueous Mounting Medium (Sigma). 
Stained tissue sections were then imaged by fluorescence microscopy.
Biodistribution studies. quantification of gold nanobeacons accumulation in the tumor and other 
organs. Biodistribution of the functionalized gold nanobeacons in tissues associated with clearance 
(liver, spleen and kidney) as well as the gastric tumor, lung and heart was measured by inductively 
coupled plasma mass spectrometry (ICP-MS). Briefly, 5 days after gold nanobeacons administration, the 
mice were sacrificed to harvest the major organs, which were rinsed with ethanol three times and then 
air-dried into clean vials for acid digestion (aqua-regia 3HCl:1HNO3). After 1 day of strong acid diges-
tion, the samples were analyzed by ICP-MS.
Statistics. Differences between groups were examined using Student’s paired t test through SPSS sta-
tistical package (version 17, SPSS Inc.). All error bars used in this report are mean ± SD of at 3 independ-
ent experiments. Statistically significant P values were indicated in figures and/or legends as ***P < 0.005; 
**P < 0.01; *P < 0.05. All in vivo experiments used 5 mice per treatment group unless noted otherwise.
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